<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ERY- erythromycinÂ solutionÂ </strong><br>Perrigo New York Inc<br></p></div>
<h1>Ery 2% Pads <br>(Erythromycin Pledgets USP, 2%)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4cacb9e6-777f-489c-89ab-0b1eae3e3bd0"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx Only</span></p>
<p><span class="Bold">For Dermatologic Use Only</span></p>
<p><span class="Bold">Not for Ophthalmic Use</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_71bdde01-b042-4557-a348-653e5f6a0a5f"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Ery 2% Pads contain erythromycin, USP for topical dermatologic use. Erythromycin is a macrolide antibiotic produced from a <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of <span class="Italics">Saccaropolyspora erythraea </span>(formerly <span class="Italics">Streptomyces erythreus</span>). It is a base and readily forms salts with acids.</p>
<p>Chemically, erythromycin is C<span class="Sub">37</span>H<span class="Sub">67</span>NO<span class="Sub">13</span>. It has the following structural formula:</p>
<div class="Figure"><img alt="Chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9a63da11-01be-4c63-a260-e6bdbb4a7a69&amp;name=0c77c8df-3dac-4a7a-abea-71884137e216-01.jpg"></div>
<p>The chemical name for erythromycin is (3<span class="Italics">R</span>*,4<span class="Italics">S</span>*,5<span class="Italics">S</span>*,6<span class="Italics">R</span>*,7<span class="Italics">R</span>*,9<span class="Italics">R</span>*,11<span class="Italics">R</span>*,12<span class="Italics">R</span>*,13<span class="Italics">S</span>*,14<span class="Italics">R</span>*)-4-[(2,6-Dideoxy-3-<span class="Italics">C</span>-methyl-3-<span class="Italics">O</span>-methyl-Î±-L-<span class="Italics">ribo</span>-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-Î²-D-<span class="Italics">xylo</span>-hexopyranosyl]oxy] oxacyclotetradecane-2,10-dione.</p>
<p>Erythromycin has the molecular weight of 733.94. It is a white or slightly yellow, crystalline powder, slightly soluble in water, soluble in alcohol, in chloroform, and in ether. It is odorless or practically odorless. It has a pH range between 8.0 and 10.5 in a methanol and water solution prepared by diluting 1 volume of a methanol solution, containing 40 mg per mL, with 19 volumes of water.</p>
<p>Each mL of expressible liquid contains 20 mg erythromycin in a base of dehydrated alcohol, propylene glycol and citric acid to adjust pH. Each pledget is filled to contain 0.8 mL of Erythromycin Topical Solution 2%.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_4be66912-f18f-43a5-85ba-c7203803434a"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">The exact mechanism by which erythromycin reduces lesions of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span> is not fully known; however, the effect appears to be due in part to the antibacterial activity of the drug.</p>
<div class="Section" data-sectionCode="49489-8">
<a name="i4i_microbiology_id_974e1e88-692d-4876-8716-fceba1830fc9"></a><a name="section-3.1"></a><p></p>
<h2>MICROBIOLOGY</h2>
<p class="First">Erythromycin acts by inhibition of protein synthesis in susceptible organisms by reversibly binding to 50S ribosomal subunits, thereby inhibiting translocation of aminoacyl transfer-RNA and inhibiting polypeptide synthesis. Antagonism has been demonstrated <span class="Italics">in vitro </span>between erythromycin, lincomycin, chloramphenicol, and clindamycin.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_e29ec425-11a3-4f39-a06e-52924e680d44"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Ery 2% Pads are indicated for the topical treatment of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_09073a17-1daf-436c-8c53-8300806ad672"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Ery 2% Pads are contraindicated in those individuals who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of its components.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_51ce23ec-80be-4bcc-a511-4e0b866d3e0c"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span> has been reported with nearly all antibacterial agents, including erythromycin, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> subsequent to the administration of antibacterial agents.</span></p>
<p>Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by <span class="Italics">Clostridium difficile </span>is one primary cause of â€œantibiotic-associated colitisâ€?.</p>
<p>After the diagnosis of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> has been established, therapeutic measures should be initiated. Mild cases of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation and treatment with an antibacterial drug clinically effective against <span class="Italics">C. difficile </span><span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_9a20b1b1-7d88-431f-8de6-14002161d983"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_3c60cb50-26dc-463d-bfa5-1ce2d4840f53"></a><a name="section-7.1"></a><p></p>
<h2>General -</h2>
<p class="First">For topical use only; not for ophthalmic use. Concomitant topical <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> therapy should be used with caution because a possible cumulative irritancy effect may occur, especially with the use of <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span>, desquamating, or abrasive agents.</p>
<p>The use of antibiotic agents may be associated with the overgrowth of antibiotic-resistant organisms. If this occurs, discontinue use and take appropriate measures.</p>
<p>Avoid contact with eyes and all mucous membranes.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_865d88da-1df4-41db-92ba-35e567a9f9bf"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients -</h2>
<p class="First">Patients using Ery 2% Pads should receive the following information and instructions:</p>
<p>1. This medication is to be used as directed by the physician. It is for external use only.    Avoid contact with the eyes, nose, mouth, and all mucous membranes.</p>
<p>2. This medication should not be used for any disorder other than that for which it was prescribed.</p>
<p>3. Patients should not use any other topical <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> medication unless otherwise directed by their physician.</p>
<p>4. Patients should report to their physician any signs of local adverse reactions.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_a6b57212-65da-404e-a3ac-e920ae56e92d"></a><a name="section-7.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility -</h2>
<p class="First">No animal studies have been performed to evaluate the carcinogenic and mutagenic potential or effects on fertility of topical erythromycin. However, long-term (2-year) oral studies in rats with erythromycin ethylsuccinate and erythromycin base did not provide evidence of tumorigenicity. There was no apparent effect on male or female fertility in rats fed erythromycin (base) at levels up to 0.25% of diet.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_63809e07-3a7f-4c2f-82ee-4c8e60e30466"></a><a name="section-7.4"></a><p></p>
<h2>Pregnancy:</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_8a6fa7ff-a558-429b-a62b-e5aa7c87b35d"></a><a name="section-7.4.1"></a><p></p>
<h3>Teratogenic Effects:</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8e20a95b-aa17-47fc-8332-5efdd5d1a07c"></a><a name="section-7.4.1.1"></a><p></p>
<h4>Pregnancy Category B -</h4>
<p class="First">There was no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> or any other adverse effect on reproduction in female rats fed erythromycin base (up to 0.25% diet) prior to and during mating, during gestation and through weaning of two successive litters.</p>
<p>There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used in pregnancy only if clearly needed. Erythromycin has been reported to cross the placental barrier in humans, but fetal plasma levels are generally low.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_011a2c3d-3f4c-4903-8590-c620f5c965be"></a><a name="section-7.5"></a><p></p>
<h2>Nursing Women -</h2>
<p class="First">It is not known whether erythromycin is excreted in human milk after topical application. However, erythromycin is excreted in human milk following oral and parenteral erythromycin administration. Therefore, caution should be exercised when erythromycin is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_d4ee348e-bf95-418c-81e1-d15a5dbebab3"></a><a name="section-7.6"></a><p></p>
<h2>Pediatric Use -</h2>
<p class="First">Safety and effectiveness of this product in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_9b57b92f-cc65-474e-936f-30cbf37d8854"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The following local adverse reactions have been reported occasionally: <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span>, dryness, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, and oiliness. Irritation of the eyes and <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> of the skin have also been reported with topical use of erythromycin. Generalized urticarial reactions, possibly related to the use of erythromycin, which required systemic steroid therapy have been reported.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_c98c4729-0380-45a6-9e11-3958187a4647"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The Ery 2% Pads should be rubbed over the affected area twice a day (morning and evening) after skin is thoroughly washed with warm water and soap and patted dry. <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span> lesions on the face, neck, shoulders, chest, and back may be treated in this manner. Additional pledgets may be used, if needed. Each pledget should be used once and discarded. Wash hands after application. Close jar tightly after each use. Drying and <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span> may be controlled by reducing the frequency of applications.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_80f6fba6-29ae-422a-9595-0599858c2869"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Ery 2% Pads are available as follows:</p>
<p>A plastic jar containing 60 pledgets (NDC 45802-<span class="Bold">962</span>-72)</p>
<p>Each pledget is filled to contain 0.8 mL of Erythromycin Topical Solution 2%.</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_c9631836-1821-4125-9a74-fdc93accf5e0"></a><a name="section-11"></a><p></p>
<h1>STORAGE</h1>
<p class="First">Keep jar tightly closed.</p>
<p>Store at 20-25Â°C (68-77Â°F) [see USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fd990a97-d9a1-4958-bf7b-c3cf7e04cac3"></a><a name="section-12"></a><p></p>
<p class="First">Made in Israel</p>
<p>Manufactured by Perrigo</p>
<p>Yeruham 80500, Israel</p>
<p><img alt="Image 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9a63da11-01be-4c63-a260-e6bdbb4a7a69&amp;name=0c77c8df-3dac-4a7a-abea-71884137e216-02.jpg"></p>
<p>Rev. 08/11</p>
<p>6E500 RC J4</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_55305715-631f-4565-8442-ad4be0aaae28"></a><a name="section-13"></a><p></p>
<h1>Principal Display Panel</h1>
<p class="First">Rx Only</p>
<p>Ery 2% Pads (Erythromycin Pledgets USP, 2%)</p>
<p>For External Use</p>
<p>Avoid Contact with Eyes</p>
<div class="Figure">
<img alt="Ery 2% Pads (Erythromycin Pledgets USP, 2%) Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9a63da11-01be-4c63-a260-e6bdbb4a7a69&amp;name=0c77c8df-3dac-4a7a-abea-71884137e216-03.jpg"><p class="MultiMediaCaption">Ery 2% Pads (Erythromycin Pledgets USP, 2%) Label</p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ERYÂ 		
					</strong><br><span class="contentTableReg">erythromycin solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:45802-962</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ERYTHROMYCIN</strong> (ERYTHROMYCIN) </td>
<td class="formItem">ERYTHROMYCIN</td>
<td class="formItem">0.8Â mL Â inÂ 100Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:45802-962-72</td>
<td class="formItem">60  in 1 JAR</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">0.8 mL in 1 APPLICATOR</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA064126</td>
<td class="formItem">07/07/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Perrigo New York Inc
							(078846912)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 11/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>0c77c8df-3dac-4a7a-abea-71884137e216</div>
<div>Set id: 9a63da11-01be-4c63-a260-e6bdbb4a7a69</div>
<div>Version: 5</div>
<div>Effective Time: 20111109</div>
</div>
</div>Â <div class="DistributorName">Perrigo New York Inc</div></p>
</body></html>
